Affibody, ACELYRIN, and Inmagene Biopharmaceuticals, have announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis. The double-blind, placebo-controlled Phase 2 clinical trial, desiAlready a subscriber Login You have read all your free articles,…